Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutimlimab in primary cold agglutinin disease (Cadenza)
NCT03347422Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2018
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of sutimlimab in cold agglutinin disease (CAD), sponsored by Sanofi. Started Mar 2018; status: completed.
02
Drugs
sutimlimab
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT03347422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347422.